Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Primary Antiphospholipid Syndrome
NCT06315530Phase 2Completed
- Sponsor
- Ruijin Hospital
- Start
- Dec 2023
- Primary completion
- Apr 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of telitacicept in antiphospholipid syndrome (APS) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Proportion of patients with decreased antiphospholipid antibody titer at 48 weeks. Started Dec 2023; status: completed.
02
Drugs
telitacicept
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT06315530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06315530.